Clearmind Medicine Inc. (TSE:CMND) has released an update.
Clearmind Medicine Inc., a biotech firm specializing in psychedelic-derived therapeutics, has received approval to voluntarily delist its common shares from the Canadian Securities Exchange to streamline trading on the NASDAQ, where shares will continue to be available under the symbol CMND. The company anticipates that this move, effective March 14, 2024, will concentrate the marketplace, potentially enhancing long-term shareholder value and liquidity. Shareholders are advised to consult their brokers regarding trading on NASDAQ post-delisting.
For further insights into TSE:CMND stock, check out TipRanks’ Stock Analysis page.
